Strategies to prolong the intravaginal residence time of drug delivery systems

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 3, 2009, Pages 312-336

  Baloglu, Esra ^a   Senyigit, Zeynep Ay ^a   Karavana, Sinem Y ^a   Bernkop Schnürch, Andreas ^b  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BLEOMYCIN; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; BUFFER GEL; CALCITONIN; CHITOSAN; CISPLATIN; CLOTRIMAZOLE; FLUCONAZOLE; FLUOROURACIL; GONADORELIN ANTAGONIST; HUMAN GROWTH HORMONE; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; LACTIC ACID; METRONIDAZOLE; MISOPROSTOL; MONOCLONAL ANTIBODY; OXYTOCIC AGENT; OXYTOCIN; POLYACRYLIC ACID; POLYCARBOPHIL; POLYSTYRENESULFONIC ACID; PROPRANOLOL; PROSTAGLANDIN; SPERMICIDAL AGENT; STAMPIDINE; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVAL;

AGAR PLATE METHOD; ANALYTIC METHOD; BIOADHESIVE FORCE DETERMINATION DEVICE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; ELECTROMAGNETIC FORCE TRANSDUCER TECHNIQUE; FLOW MEASUREMENT; FLOWING LIQUID FILM TECHNIQUE; GAMMA SCINTIGRAPHY; GELATION; GLASS SPHERE METHOD; HUMAN; IONIC STRENGTH; LOWERING PLATFORM; MAXIMUM PLASMA CONCENTRATION; MODIFIED DUAL TENSIOMETER METHOD; MODIFIED SETNIKAR FANTELI TECHNIQUE; MUCIN GOLD STAINING METHOD; MUCOADHESION; OXIDATION; PH MEASUREMENT; PHASE TRANSITION; REVIEW; ROTATING CYLINDER TECHNIQUE; SEXUALLY TRANSMITTED DISEASE; TABLET FORMULATION; TEXTURE ANALYZER; THERAPY; WILHELMY PLATE SURFACE TECHNIQUE; AGING; ANIMAL; CHEMISTRY; FEMALE; HISTOLOGY; INSTRUMENTATION; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MUCOSA; PHARMACOKINETICS; PHYSIOLOGY; TIME; VAGINA;

ADMINISTRATION, INTRAVAGINAL; AGING; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MUCOUS MEMBRANE; PHARMACOKINETICS; TIME FACTORS; VAGINA;

EID: 77950361652     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3hp41     Document Type: Review

References (148)

1. Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharm Sci Technolo Today, 3:359-364, 2000.
2. Richardson JL, Illum L. Routes of delivery: Case studies: The vaginal route of peptide and protein drug delivery. Adv Drug Deliv Rev, 8:341-366, 1992.
3. Robinson JR, Bologna WJ. Vaginal reproductive system treatments using a bioadhesive polymer. J Control Release, 28:87-94, 1994.
4. Valenta C. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev, 57:1692-1712, 2005.
5. Pendergrass PB, Belovicz MW, Reeves CA. Surface area of the human vagina as measured from vinyl polysiloxane casts. Gynecol Obstet Invest, 55:110-113, 2003.
6. Weber AE, Walters MD, Schover LR. Vaginal anatomy and sexual function. Obstet Gynecol, 86:946-949, 1995.
7. Vagina, The Free Histology Encyclopedia, Available at: http://www.ihcworld.com/histowiki/ doku.php?id=vagina
8. Platzner W, Poisel S, Hafez ESE. Functional anatomy of the human vagina. In: Hafez ESE, Evans TN (eds). Human reproductive medicine: the human vagina. North Holland Publishing, New York, pp 39-54, 1978.
9. Wagner G, Levin RJ. Vaginal fluid. In: Hafez ESE, Evans TN (eds). Human reproductive medicine: the human vagina. North Holland Publishing, New York, pp 121-137, 1978.
10. Bernkop-Schnürch A. Mucoadhesive Polymers. In: Dumitriu S (eds). Polymeric Biomaterials. Marcel Dekker, New York, pp 147-165, 2002.
11. Muir GG. Multiple enzyme studies in the vaginal fluid in relation to benign and malignant gynaecological conditions. Br J Cancer, 20:448-462, 1966.
12. Goldberg DM, Hart DM, Watts C. Distribution of enzymes in human vaginal fluid: relevance to the diagnosis of cervical cancer. Cancer, 21:964-973, 1968.
13. Paavonen J. Physiology and ecology of the vagina. Scand J Infect Dis, 40:31-35, 1983.
14. Owen DH, Katz DF. A vaginal fluid stimulant. Contraception, 9:91-95, 1999.
15. Justin-Temu M, Damian F, Kinget R, Van Den Mooter G. Intravaginal gels as drug delivery systems. J Womens Health, 13:834-844, 2004.
16. Woolfson AD, Malcolm RK, Gallagher R. Drug delivery by the intravaginal route. Crit Rev Ther Drug Carr Syst, 17:509-555, 2000.
17. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm, 255:13-32, 2003.
18. El-Kamel A, Sokar M, Naggar V, Al-Gamal S. Chitosan and sodium alginate-based bioadhesive vaginal tablets. AAPS PharmSci, 4:44, 2002.
19. Bonferoni MC, Giunchedi P, Scalia S, Rossi S, Sandri G, Caramella C. Chitosan gels for the vaginal delivery of lactic acid: relevance of formulation parameters to mucoadhesion and release mechanisms. AAPS PharmSciTech, 7:104, 2006.
20. Francois M, Snoeckx E, Putteman P, Wouters F, De Proost E, Delaet U, Peeters J, Brewster ME. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci, 5:5, 2003.
21. Garg S, Vermani K, Garg A, Anderson RA, Rencher WB, Zaneveld LJD. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res, 22:584-595, 2005.
22. D'Cruz OJ, Samuel P, Waurzyniak B, Uckun FM. Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broadspectrum anti-human immunodeficiency virus microbicide. Biol Reprod, 69:1843-1851, 2003.
23. Bilensoy E, Çi{dotless}rpanli{dotless} Y, Şen M, Doǧan AL, Çali{dotless}ş S. Thermosensitive mucoadhesive gel formulation loaded with 5-Fu:cyclodextrin complex for HPV-induced cervical cancer. J Incl Phenom Macrocycl Chem, DOI 10.1007/s10847-006-9259-y.
24. Bilensoy E, Rouf MA, Vural I, Şen M, Hi{dotless}ncal AA. Thermosensitive, prolonged-release vaginal gel for clotrimazole:β-cyclodextrin complex. AAPS PharmSciTech, 7:38, 2006.
25. Keskar V, Mohanty PS, Gemeinhart EJ, Gemeinhart RA. Cervical cancer treatment with a locally insertable controlled release delivery system. J Control Release, 115:280-288, 2006.
26. Ndesendo VMK, Pillay V, Choonara YE, Buchmann E, Bayever DN, Bachav LYG, Patravale VB. Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation. Int J Pharm, 365:175-179, 2009.
27. Meyer C. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infectious. AAPS PharmSciTech, 9:505-519, 2008.
28. Vermesh M, Fossum GT, Kletzky OA. Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Obstet Gynecol, 72:693-698, 1988.
29. Jasonni VM, Raffelli R, March A, Frank G, Flamigni C. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet Gynecol Scand, 70:493-495, 1991.
30. Darwish AM. Clinical assessment of unique buccal vs vaginal mucoadhesive bromocryptine mesylate discs for treting hyperprolactinemic women Fertil Steril, 84:159-160, 2005.
31. Patel LG. Propanolol concentration in plasma after insertion into the vagina. Br Med J, 287:1247-1248, 1984.
32. Christensen FC, Tehranifar M, Gonzales JL, Qualls CR, Rappaport VJ, Rayburn WF. Randomized trial of concurrent oxytocin with a sustained-release dinoprostone vaginal insert for labor induction at term. Am J Obstet Gynecol, 186:61-65, 2002.
33. Agarwal N, Gupta A, Kriplani A, Bhatla NP. Six hourly vaginal misoprostol versus intracervical dinoprostone for cervical ripening and labor induction. J Obstet Gynaecol Res, 29:147-151, 2003.
34. Richardson JL, Trevor TI. Vaginal delivery of calcitonin by hyaluronic acid formulations. Drugs Pharm Sci, 98:563-599, 1999.
35. Han K, Park JS, Chung YB, Jeong NJP, Park HB, Robinson JR. Development of luteinizing hormone releasing hormone (LH-RH) delivery systems for vaginal mucosal route. Arch Pharm Res, 18:325-331, 1995.
36. Livingston JB, Lu S, Robinson H, Anderson DJ. Immunization of the female genital tract with a DNA-based vaccine. Infect Immun, 66:322-329, 1998.
37. Nyende L, Towobola OA, Mabina MH. Comparison of vaginal and oral misoprostol, for the induction of labour in women, with intra-uterin foetal death. East Afr Med J, 81:179-182, 2004.
38. Bilensoy E, Rouf MA, Vural I, Şen M, Hi{dotless}ncal AA. Mucoadhesive, Thermosensitive, Prolonged-Release Vaginal Gel for Clotrimazole: β-Cyclodextrin Complex. AAPS PharmSciTech, 7:E1-E7, 2006.
39. Zieman M, Fong SK, Benowitz NL, Bankster D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol, 90:88-92, 1997.
40. th Edition, 3:1585-1594, 1996.
41. Neves J, Bahia MF. Gels as vaginal drug delivery systems. Int J Pharm, 318:1-14, 2006.
42. Baloǧlu E, Özyazi{dotless}ci{dotless} M, Hi{dotless}zarci{dotless}oǧlu SY, Şenyiǧit T, Özyurt D, Pekçetin Ç. Bioadhesive Controlled Release Systems of Ornidazole for Vaginal Delivery. Pharm Dev Technol, 11:477-484, 2006.
43. Bernkop-Schnürch A, Hornof M. Intravaginal drug delivery systems design, challenges, and solutions. Am J Drug Deliv, 1:241-254, 2003.
44. Lucy MC, Billings HJ, Butler WR. Efficacy of an intravaginal progesteron insert and an injection of PGF2 alpha for synchronizing estrus and shortening the interval to pregnancy in post partum beef cows, peripubertal beef heifers and dairy heifers. J Anim Sci, 79:982-995, 2001.
45. Brown J, Hooper G, Kenyon CJ. Spreading and retention of vaginal formulations in postmenopausal women as assessed by gamma scintigraphy. Pharm Res, 14:1073-1078, 1997.
46. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release, 103:301-313, 2005.
47. Garg S, Tambwekar KR, Vermani K, Kandarapu R, Garg A, Waller DP, Zaneveld LJD. Development pharmaceutics of microbicide formulations, Part II: Formulation, evaluation and challenges. AIDS Patient Care STDs, 17:377-399, 2003.
48. Merabet J, Thompson D, Saul Levinson R. Advancing vaginal drug delivery. Expert Opin Drug Deliv, 2:769-777, 2005.
49. Iyer V, Bendgude N, Poddar SS. Vaginal drug delivery. Available at: http://www.expresspharmaonline.com/200807 15/research02.shtml
50. Chowdary KPR, Rao YS. Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: A technical note. AAPS PharmSciTech, 4(3):39, 2003.
51. Batchelor H. Novel bioadhesive formulations in drug delivery. The Drug Delivery Companies Report, Autumn/Winter, Technology/Industry Overwievs, 16-19, 2004.
52. Bonacucina G, Martelli S, Palmieri GF. Rheological, mucoadhesive and release properties of Carbopol gels in hydrophilic cosolvents. Int J Pharm, 282:115-130, 2004.
53. Fabio S, Van Roey J, Giannini G, Mooter G, Spada M, Binelli A, Pirillo MF, Germinario E, Belardelli F, Bethune MP, Vella S. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS, 17:1597-1604, 2003.
54. Geonnotti AR, Peters JJ, Katz DF. Erosion of microbicide formulation coating layers: effects of contact and shearing with vaginal fluid or semen. J Pharm Sci, 94:1705-1712, 2005.
55. Washington N, Washington C, Wilson CG (eds). Vaginal and intrauterine drug delivery, Physiological Pharmaceutics: Barriers to Drug Absorption, CRC Press, London, pp 272-281, 2000.
56. Deǧim Z, Deǧim T, Acartürk F, Erdoǧan D, Özoǧul C, Köksal M. Rectal and vaginal administration of insulin-chitosan formulations: An experimental study in rabbits. J Drug Target, 13:563-572, 2005.
57. Cevher E, Taha MAM, Orlu M, Araman A. Evaluation of Mechanical and Mucoadhesive Properties of Clomiphene Citrate Gel Formulations Containing Carbomers and Their Thiolated Derivatives. Drug Deliv, 15:57-67, 2008.
58. Chopra S, Motwani SK, Iqbal Z, Talegaonkar S, Ahmad FJ, Khar RK. Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. Eur J Pharm Biopharm, 67:120-131, 2007.
59. Garg S, Anderson RA, Chany CJ, Waller DP, Diao XH, Vermani K, Zaneveld LJD. Properties of a new acid-buffering bioadhesive vaginal formulation (Acidform). Contraception, 64:67-75, 2001.
60. Amaral E, Perdigao A, Souza MH, Mauck C, Waller D, Zaneveld L, Faundes A. Vaginal safety after use of a bioadhesive, acidbuffering, microbicidial contraceptive gel (Acidform) and a 2% nonxynol-9 product. Contraception, 73:542-547, 2006.
61. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm, 71:505-518, 2009.
62. Balicka-Ramisz A, Wojtasz-Pajak A, Pilarczykl B, Ramisz A, Laurans L, Antibacterial and antifungal activity of chitosan. ISAH, 2:406-408, 2005.
63. Seyfarth F, Schliemann S, Elsner P, Hipler UC. Antifungal effect of high-and lowmolecular-weight chitosan hydrochloride, carboxymethyl chitosan, chitosan oligosaccharide and N-acetyl-d-glucosamine against Candida albicans, Candida krusei and Candida glabrata. Int J Pharm, 353:139-148, 2008.
64. Microbicide Research and Development Database, 2005, Alliance for Microbicide Development. Accessed July 21, 2007 Available at: http://secure.microbicide.org/NetReports/ ClinicalTrialsOngoingByProduct.aspx
65. Mitchel D. Focus renewed on HIV microbicides. International Health Conference, Canada, 2006.
66. Alam MA, Ahmad FJ, Iqubal ZI, Khan ZI, Khar RK, Ali M. Development and evaluation of acid-buffering bioadhesive vaginal tablet for mixed vaginal infections. AAPSPharmSciTech, 8:109, 2007.
67. Mandal TK. Swelling-controlled release system for the vaginal delivery of miconazole. Eur J Pharm Biopharm, 50:337-343, 2000.
68. Ghezzo E, Benedetti L, Rochira N, Biviano F, Callegaro L. Hyaluronane derivative microsphere as NGF delivery device: Preparation methods and in vitro release characterization. Int J Pharm, 87:21-29, 1992.
69. Richardson JL, Armstrong TI. Vaginal delivery of calcitonin by hyaluronic acid formulations. In: Mathiowitz E, Chickering DE, Lehr CM (eds). Bioadhesive Drug Delivery Systems-Fundamentals, Novel approaches and Development. Marcel Dekker, New York, pp 563-599, 1999.
70. O'Hagan DT, Raffery D, Wharton S, Illum L. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine, 11:660-664, 1993.
71. O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 34:305-320, 1998.
72. Esposito E, Menegatti E, Cortesi R. Hyaluronan-based microspheres as tools for drug delivery: a comparative study. Int J Pharm, 288:35-49, 2005.
73. Bonucci E, Ballanti P, Ramires A, Richardson JL, Benedetti LM. Prevention of ovariectomy osteopenia in rats after vaginal administration of hyaff 11 microspheres containing salmon calcitonin. Calcif Tissue Int, 56:274-279, 1995.
74. Yoo JW, Dharmala K, Lee CH. The physicodynamic properties of mucoadhesive polymeric films developed as female controlled drug delivery system. Int J Pharm, 309:139-145, 2006.
75. Choy YB, Park JH, Prausnitz MR. Mucoadhesive microparticles engineered for ophthalmic drug delivery. J Phys Chem Solids, 69:1533-1536, 2008.
76. Thirawong N, Kennedy RA, Sriamornsak P. Viscometric study of pectin-mucin interaction and its mucoadhesive bond strength. Carbohyd Polym, 71:170-179, 2008.
77. Wu N, Dai J, Micale FJ. Dynamic surface tension measurement with a dynamic Wilhelmy Plate technique. J Colloid Interf Sci, 215:258-269, 1999.
78. Mikos AG, Peppas NA. Systems for controlled release of drugs V: Bioadhesive systems. STP Pharma Sci, 19:705-715, 1986.
79. Wong C, Yuen K, Peh K. An in-vitro method for buccal adhesion studies: importance of instrument variables. Int J Pharm, 180:47-57, 1999.
80. Yong CS, Choi JS, Quan QZ, Rhee JD, Kim CK, Lim SJ, Kim KM, Oh PS, Choi HG. Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium. Int J Pharm, 226:195-205, 2001.
81. Hertzog BA, Mathiowitz E. Novel magnetic technique to measure bioadhesion. In: Mathiowitz E, Chickering DE, Lehr CM (eds). Bioadhesive Drug Delivery Systems-Fundamentals, Novel Approaches and Development '98. Marcel Dekker, New York, pp 147-171, 1999.
82. Kast CE, Valenta C, Leopold M, Bernkop-Schnürch A. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. J Control Release, 81:347-354, 2002.
83. Bernkop-Schnürch A, Steininger S. Synthesis and characterization of mucoadhesive thiolated polymers. Int J Pharm, 194:239-247, 2000.
84. Bruschi ML, Jones DS, Panzeri H, Gremia MPD, Freitas O, Lara EHG. Semisolid systems containing propolis for the treatment of periodontal disease: In vitro release kinetics, syringeability, rheological, textural, and mucoadhesive properties. J Pharm Sci, 96:2074-2089, 2007.
85. Accili D, Menghi G, Bonacucina G, Martino P, Palmieri GF. Mucoadhesion dependence of pharmaceutical polymers on mucosa characteristics. Eur J Pharm Sci, 22:225-234, 2004.
86. Jones DS, Woolfson AD, Brown AF. Textural, viscoelastic and mucoadhesive properties of pharmaceutical gels composed of cellulose polymers. Int J Pharm, 151:223-233, 1997.
87. Garga S, Anderson RA, Chany CJ, Waller DP, Diao XH, Vermani K, Zaneveld LJD. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception, 64:67-75, 2001.
88. Alur HH, Pather SI, Mitra AK, Johnston TP. Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. Int J Pharm, 188:1-10, 1999.
89. Ceschel GC, Maffei P, Borgia SL, Ronchi C, Rossi S. Development of a mucoadhesive dosage form for vaginal administration. Drug Dev Ind Pharm, 27:541-547, 2001.
90. Leung SH, Robinson JR. The contribution of anionic polymer structural features to mucoadhesion. J Control Release, 5:223-231, 1988.
91. Bachav YG, Patravale VB, Microemulsion based vaginal gel of fluconazole: Formulation, in vitro and in vivo evaluation. Int J Pharm, 365:175-179, 2009.
92. Park K. A new approach to study mucoadhesion: colloidal gold staining. Int J Pharm, 53:209-217, 1989.
93. Ranga Rao KV, Buri P. A novel in situ method to test polymers and coated microparticles for bioadhesion. Int J Pharm, 52:265-270, 1989.
94. Teng CLC, Ho NFH. Mechanistic studies in the simultaneous flow and adsorption of polymer-coated latex particles on intestinal mucus I: Methods and physical model development. J Control Release, 6:133-149, 1987.
95. Hassan EE, Gallo JM. A simple rheological method for the in vitro assessment of mucinpolymer bioadhesive bond strength. Pharm Res, 7:491-495, 1990.
96. Jones DS, Muldoon BCO, Woolfson AD, Andrews GP, Sanderson FD. Physicochemical Characterization of Bioactive Polyacrrylic Acid Organogels as Potential Antimicrobial Implants fort he Buccal Cavity. Biomacromolecules, 9:624-633, 2008.
97. Mortazavi SA, Carpenter BG, Smart JD. An investigation of the rheological behaviour of the mucoadhesive/mucosal interface. Int J Pharm, 83:221-225, 1982.
98. Mauck CK, Katz D, Sandefer EP, Nasution MD, Henderson M, Digenis GA, Su I, Page R, Barnhart K. Vaginal distribution of Replens® and K-Y® Jelly using three imaging techniques. Contraception, 77:195-204, 2008.
99. 99mTc-DTPA labelled vaginal dosage forms. Int J Pharm, 271:137-143, 2004.
100. Richardson JL, Whetstone J, Fisher AN, Watts P, Farraj NF, Hinchcliffe M, Benedetti L, Illum L. Gamma-scintigraphy as a novel method to study the distribution and retention of a bioadhesive vaginal delivery system in sheep. J Control Release, 42:133-142, 1996.
101. Oh YK, Park JS, Yoon H, Kim CK. Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine, 21:1980-1988, 2003.
102. Chang JY, Oh YK, Choi H, Kim YB, Kim CK. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm, 241:155-163, 2002.
103. Ruel-Gariépy E, Leroux JC. In situ-forming hydrogels-review of temperature-sensitive systems. Eur J Pharm Biopharm, 58:409-426, 2004.
104. Ti{dotless}rnaksi{dotless}z F, Robinson JR. Rheological, mucoadhesive and release properties of pluronic F-127 gel and pluronic F-127/polycarbopil mixed gel systems. Pharmazie, 60:518-523, 2005.
105. Chang JY, Oh YK, Kong HS, Kim EJ, Jang DD, Nam KT, Kim CK. Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels on vaginitis. J Control Release, 82:39-50, 2002.
106. Madsen F, Eberth K, Smart JD. A rheological examination of the mucoadhesive/mucus interaction: the effect of mucoadhesive type and concentration. J Control Release, 50:167-178, 1998.
107. Tamburic S, Craig DQ. An investigation into the rheological, dielectric and mucoadhesive properties of poly(acrylic acid) gel systems. J Control Release, 37:59-68, 1995.
108. Baloǧlu E, Karavana SY, Ay Z, Güneri T. Texture Analysis of Vaginal Bioadhesive Gel Formulations of Miconazole Nitrate. Pharmaceutical Sciences World Congress, Amsterdam, DD-P-005, 2007.
109. Weidner J. Improved therapy for yeast infection through use of mucoadhesive thermosensitive gels. Drug Discov Today, 7:1230-1231, 2002.
110. Thapar MA, Parr EL, Bozzola JJ, Parr MB. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM). Vaccine, 9:129-133, 1991.
111. Mourya VK, Inamdar NN. Chitosanmodifications and applications: opportunities galore. React Funct Polym, 68:1013-1051, 2008.
112. He C, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release, 127:189-207, 2008.
113. Alexandridis P, Holzwarth JF. Differential Scanning Calorimetry Investigation of the Effect of Salts on Aqueous Solution Properties of an Amphiphilic Block Copolymer (Poloxamer). Langmuir, 13:6074-6082, 1997.
114. Ding S. Recent developments in ophthalmic drug delivery. PSTT, 1:328-335, 1998.
115. Ceulemans J, Vinckier I, Ludwig A. The use of xanthan gum in an ophthalmic liquid dosage form: rheological characterization of the interaction with mucin. J Pharm Sci, 91:1117-1127, 2002.
116. Valenta C, Nowack E, Bernkop-Schnürch A. Deoxycholate-hydrogels: Novel drug carrier systems for topical use. Int J Pharm, 185:103-111, 1999.
117. Voorspoels J, Casteels M, Remon JP, Temmerman M. Local treatment of bacterial vaginosis with a bioadhesive metronidazole tablet. Eur J Obstet Gynecol Reprod Biol, 105:64-66, 2002.
118. Brannon-Peppas L. Novel vaginal drug release applications. Adv Drug Deliv Rev, 11:169-177, 1993.
119. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv. Rev. 58:686-706, 2006.
120. Almeida A, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev, 59:478-490, 2007.
121. Saltzman WM, Sherwood JK, Adams DR, Haller P. Long-term vaginal antibody delivery: delivery systems and biodistribution. Biotechnol Bioeng, 67:253-264, 2000.
122. Parr MB, Kepple L, McDermott MR, Drew MD, Bossola JJ, Parr EL. A mouse model for studies of mucosal immunity to vaginal infection by herpex simplex virus type 2. Lab Invest, 70:369-380, 1994.
123. Wira CR, Rossoll RM. Antigen-presenting cells in the female reproductive tract: Influence of sex hormones on antigen presentation in the vagina. Immunology, 84:505-508, 1995.
124. Wira CR, Rossoll RM, Kaushic C. Antigenpresenting cells in the female reproductive tract: Influence of estradiol on on antigen presentation by vaginal cells. Endocrinology, 141:2877-2885, 2000.
125. Shen H, Goldberg E, Saltzman WM. Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix. J Control Release, 86:339-348, 2003.
126. Malcolm RK, McCullagh S, Woolfson AD, Catney M, Tallon P. A dynamic mechanical method for determining the silicon elastomer solubility of drugs and pharmaceutical excipients in silicon intravaginal drug delivery rings. Biomaterial, 23:3589-3594, 2002.
127. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. Why consider vaginal drug administration? Fertil Steril, 82:1-12, 2004.
128. Woolfson AD, Elliott G RE, Gilligan CA, Passmore CM. Design of an intravaginal ring for the controlled delivery of 17β-estradiol as its 3-acetate ester. J Control Release, 61:319-328, 1999.
129. Gupta S. Non-oral hormonal contraception. Curr Obstet Gynaecol, 16:30-38, 2006.
130. Sitruk-Ware R, Small M, Kumar N, Tsong Y, Sundaram K, Jackanicz T. Nestorone®: clinical applications for contraception and HRT. Steroids, 68:907-913, 2003.
131. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm, 54:107-117, 2002.
132. Nutter NM. Method of using lectins for contraception. Patent no: 5766632. Available at: http://www.freepatentsonline.com/5766632.html
133. Lehr CM. Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release, 65:19-29, 2000.
134. Wirth M, Gerhardt K, Wurm C, Gabor F. Lectin-mediated drug delivery: influence of mucin on cytoadhesion of plant lectins in vitro. J Control Release, 79:183-191, 2002.
135. Haltner E, Easson JH, Lehr CM. Lectins and bacterial invasion factors for controlling endoand transcytosis of bioadhesive drug carrier systems. Eur J Pharm Biopharm, 44:1-13, 1997.
136. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm, 325:82-89, 2006.
137. Malcolm RK, Woolfson AD, Toner C, Morrow RJ, McCullagh SD. Long-term, controlled release of the HIV microbicide TMC120 from silicon elastomer vaginal rings. J Antimicrob Chemother, 56:954-956, 2005.
138. Bernkop-Schnürch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliver Rev, 57:1569-1582, 2005.
139. Valenta C, Kast CE, Harich I, Bernkop-Schnürch A. Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone. J Control Release, 77:323-332, 2001.
140. Leitner VM, Walker GF, Bernkop-Schnürch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur J Pharm Biopharm, 56:207-214, 2003.
141. Hornof MD, Kast CE, Bernkop-Schnürch A. In vitro evaluation of the viscoelastic properties of chitosan-thioglycolic acid conjugates. Eur J Pharm Biopharm, 55:185-190, 2003.
142. Perioli L, Ambrogi V, Venezia L, Pagano C, Ricci M, Rossi C. Chitosan and a modified chitosan as agents to improve performances of mucoadhesive vaginal gels. Colloids Surf B Biointerfaces, 66:141-145, 2008.
143. Levinson RS, Thompson DJ. VagiSite Bioadhesive Technology. In: Rathborne M, Hadgraft J, Roberts MS (eds). Modifiedrelease Drug Delivery Technology. Marcel Dekker, New York, pp 801-806, 2003.
144. Boas U, Heegaard MH. Dendrimers in drug research. Chem Soc Rev, 33:43-63, 2004.
145. Svenson S, Tomalia DA. Dendrimers in biomedical applications-reflections on the field. Adv Drug Deliv Rev, 57:2106-2129, 2005.
146. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. The Lancet Infect Dis, 8:685-697, 2008.
147. Sashiwa H, Aiba S. Chemically modified chitin and chitosan as biomaterials. Prog Polym Sci, 29:887-908, 2004.
148. Cross PS, Künnemeyer R, Bunt CR, Carneige DA, Rathbone MJ. Control, communication and monitoring of intravaginal drug delivery in dairy cows. Int J Pharm, 282:35-44, 2004.